About: Patient blood management – a new paradigm for transfusion medicine?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Patient blood management – a new paradigm for transfusion medicine? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Patient blood management – a new paradigm for transfusion medicine?
Creator	Hofmann, A Farmer, S Isbister, J Shander, & Thomson, A
Source	Medline; PMC
abstract	The saving of many lives in history has been duly credited to blood transfusions. What is frequently overlooked is the fact that, in light of a wealth of evidence as well as other management options, a therapy deemed suitable yesterday may no longer be the first choice today. Use of blood has not been based upon scientific evaluation of benefits, but mostly on anecdotal experience and a variety of factors are challenging current practice. Blood is a precious resource with an ever limiting supply due to the aging population. Costs have also continually increased due to advances (and complexities) in collection, testing, processing and administration of transfusion, which could make up 5% of the total health service budget. Risks of transfusions remain a major concern, with advances in blood screening and processing shifting the profile from infectious to non‐infectious risks. Most worrying though, is the accumulating literature demonstrating a strong (often dose‐dependent) association between transfusion and adverse outcomes. These include increased length of stay, postoperative infection, morbidity and mortality. To this end, a recent international consensus conference on transfusion outcomes (ICCTO) concluded that there was little evidence to corroborate that blood would improve patients’ outcomes in the vast majority of clinical scenarios in which transfusions are currently routinely considered; more appropriate clinical management options should be adopted and transfusion avoided wherever possible. On the other hand, there are patients for whom the perceived benefits of transfusion are likely to outweigh the potential risks. Consensus guidelines for blood component therapy have been developed to assist clinicians in identifying these patients and most of these guidelines have long advocated more conservative ‘triggers’ for transfusion. However, significant variation in practice and inappropriate transfusions are still prevalent. The ‘blood must always be good philosophy’ continues to permeate clinical practice. An alternative approach, however, is being adopted in an increasing number of centres. Experience in managing Jehovah’s Witness patients has shown that complex care without transfusion is possible and results are comparable with, if not better than those of transfused patients. These experiences and rising awareness of downsides of transfusion helped create what has become known as ‘patient blood management’. Principles of this approach include optimizing erythropoiesis, reducing surgical blood loss and harnessing the patient’s physiological tolerance of anaemia. Treatment is tailored to the individual patient, using a multidisciplinary team approach and employing a combination of modalities. Results have demonstrated reduction of transfusion, improved patient outcomes and patient satisfaction. Significant healthcare cost savings have also followed. Despite the success of patient blood management programmes and calls for practice change, the potential and actual harm to patients caused through inappropriate transfusion is still not sufficiently tangible for the public and many clinicians. This has to change. The medical, ethical, legal and economic evidence cannot be ignored. Patient blood management needs to be implemented as the standard of care for all patients.
has issue date	2009-10-14(xsd:dateTime)
bibo:doi	10.1111/j.1751-2824.2009.01251.x
bibo:pmid	32328164
has license	no-cc
sha1sum (hex)	e9e780a8de41b51d4f27c29e4401038417dc9cdf
schema:url	https://doi.org/10.1111/j.1751-2824.2009.01251.x
resource representing a document's title	Patient blood management – a new paradigm for transfusion medicine?
has PubMed Central identifier	PMC7169263
has PubMed identifier	32328164
schema:publication	ISBT Sci Ser
resource representing a document's body	covid:e9e780a8de41b51d4f27c29e4401038417dc9cdf#body_text
is schema:about of	named entity 'blood loss' named entity 'non-significant' named entity 'anaemia' named entity 'organ' named entity 'blood loss' named entity 'Austria' named entity 'Chagas disease' named entity 'allogeneic' named entity 'Health service' named entity 'medical institutions' named entity 'platelets' named entity 'randomized controlled trials' named entity 'red cell' named entity 'randomized trial' named entity 'HDI' named entity 'parenteral' named entity 'HIV' named entity 'pathology' named entity 'transfused blood' named entity 'anaemia' named entity 'dose-dependent' named entity 'anaemia' named entity 'ESAs' named entity 'New Zealand' named entity 'TRALI' named entity 'transfusion reaction' named entity 'trauma patients' named entity 'SHOT' named entity 'haemolytic' named entity 'blood loss' named entity 'Western Australia' named entity 'cardiac surgery' named entity 'virus' named entity 'adverse events' named entity 'blood storage' named entity 'patient blood management' named entity 'multi-organ failure' named entity 'transfuse' named entity 'anaemia' named entity 'blood supply' named entity 'red cells' named entity 'cardiac events' named entity 'Englewood Hospital and Medical Center' named entity 'Australia' named entity '95% CI' named entity 'older age' named entity 'Canada' named entity 'Anaemia' named entity 'stem cell transplantation' named entity 'supply chain' named entity 'adverse events' named entity 'Jehovah's Witness' named entity 'transfuse' named entity 'mortality rates' named entity 'critically ill' named entity 'Red Cell' named entity 'observational studies' named entity 'AIDS' named entity 'United States' named entity 'haemoglobin' named entity 'human blood' named entity 'patient blood management' named entity 'erythropoiesis-stimulating agents' named entity 'chemotherapy' named entity 'patient blood management' named entity 'premature infants' named entity 'HCV' named entity 'haematological malignancy' named entity 'non-infectious' named entity 'adverse effects' named entity 'haemoglobin' named entity 'cardiac surgeon' named entity 'risk factors' named entity 'haemoglobin' named entity 'informed consent' named entity 'argon' named entity 'haemorrhagic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software